FibroBiologics, Cash vs Total Stockholder Equity Analysis
| FBLG Stock | 2.15 0.01 0.46% |
FibroBiologics, Common financial indicator trend analysis is much more than just examining FibroBiologics, Common latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether FibroBiologics, Common is a good investment. Please check the relationship between FibroBiologics, Common Cash and its Total Stockholder Equity accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroBiologics, Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Cash vs Total Stockholder Equity
Cash vs Total Stockholder Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of FibroBiologics, Common Cash account and Total Stockholder Equity. At this time, the significance of the direction appears to have strong relationship.
The correlation between FibroBiologics, Common's Cash and Total Stockholder Equity is 0.72. Overlapping area represents the amount of variation of Cash that can explain the historical movement of Total Stockholder Equity in the same time period over historical financial statements of FibroBiologics, Common Stock, assuming nothing else is changed. The correlation between historical values of FibroBiologics, Common's Cash and Total Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash of FibroBiologics, Common Stock are associated (or correlated) with its Total Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Stockholder Equity has no effect on the direction of Cash i.e., FibroBiologics, Common's Cash and Total Stockholder Equity go up and down completely randomly.
Correlation Coefficient | 0.72 |
| Relationship Direction | Positive |
| Relationship Strength | Significant |
Cash
Cash refers to the most liquid asset of FibroBiologics, Common, which is listed under current asset account on FibroBiologics, Common Stock balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from FibroBiologics, Common customers. The amounts must be unrestricted with restricted cash listed in a different FibroBiologics, Common account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Most indicators from FibroBiologics, Common's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into FibroBiologics, Common current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroBiologics, Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. At this time, FibroBiologics, Common's Issuance Of Capital Stock is most likely to increase significantly in the upcoming years. The FibroBiologics, Common's current Enterprise Value is estimated to increase to about 1 B, while Selling General Administrative is projected to decrease to roughly 2.9 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 1.6M | 4.4M | 8.9M | 9.3M | Research Development | 521K | 1.1M | 2.4M | 1.3M |
FibroBiologics, Common fundamental ratios Correlations
Click cells to compare fundamentals
FibroBiologics, Common Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Currently Active Assets on Macroaxis
When determining whether FibroBiologics, Common is a strong investment it is important to analyze FibroBiologics, Common's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact FibroBiologics, Common's future performance. For an informed investment choice regarding FibroBiologics, Stock, refer to the following important reports:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroBiologics, Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroBiologics, Common. If investors know FibroBiologics, will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroBiologics, Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.55) | Return On Assets (0.66) | Return On Equity (2.68) |
The market value of FibroBiologics, Common is measured differently than its book value, which is the value of FibroBiologics, that is recorded on the company's balance sheet. Investors also form their own opinion of FibroBiologics, Common's value that differs from its market value or its book value, called intrinsic value, which is FibroBiologics, Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroBiologics, Common's market value can be influenced by many factors that don't directly affect FibroBiologics, Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroBiologics, Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroBiologics, Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroBiologics, Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.